Vascular endothelial growth factor in predicting outcome in breast cancer

被引：6
|
作者：
Krippl, P [1 ]
Langsenlehner, U
Samonigg, H
Renner, W
Köppel, H
机构：
[1] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[2] Med Univ Graz, Inst Clin Med, Graz, Austria
[3] Med Univ Graz, Chem Lab Diagnost, Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Angiol, Graz, Austria
来源：
CLINICAL CANCER RESEARCH | 2004年 / 10卷 / 24期
关键词：
D O I：
10.1158/1078-0432.CCR-04-1211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8752 / 8753
页数：2
相关论文
共 50 条
  • [21] Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer
    Else Maae
    Dorte Aalund Olsen
    Karina Dahl Steffensen
    Erik Hugger Jakobsen
    Ivan Brandslund
    Flemming Brandt Sørensen
    Anders Jakobsen
    Breast Cancer Research and Treatment, 2012, 133 : 257 - 265
  • [22] Measurement of serum vascular endothelial growth factor in breast cancer patients
    Ferrero, S
    Nicoletti, A
    Ragni, N
    INTERNAL MEDICINE JOURNAL, 2005, 35 (05) : 310 - 311
  • [23] Quantitative analysis of vascular endothelial growth factor in primary breast cancer
    Toi, M
    Kondo, S
    Suzuki, H
    Yamamoto, Y
    Inada, K
    Imazawa, T
    Taniguchi, T
    Tominaga, T
    CANCER, 1996, 77 (06) : 1101 - 1106
  • [24] Somatostatin receptors and vascular endothelial growth factor in human breast cancer
    Raggi, CC
    Pazzagli, M
    Orlando, C
    Tricarico, C
    Gelmini, S
    Cataliotti, L
    Distante, V
    Maggi, M
    Amadori, D
    Serio, M
    ADVANCES IN GYNECOLOGICAL ENDOCRINOLOGY, 2002, : 307 - 311
  • [25] Vascular endothelial growth factor receptor-2 in breast cancer
    Guo, Shanchun
    Colbert, Laronna S.
    Fuller, Miles
    Zhang, Yuanyuan
    Gonzalez-Perez, Ruben R.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2010, 1806 (01): : 108 - 121
  • [26] Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel
    Koutras, A. K.
    Kotoula, V.
    Papadimitriou, C.
    Dionysopoulos, D.
    Zagouri, F.
    Kalofonos, H. P.
    Kourea, H. P.
    Skarlos, D. V.
    Samantas, E.
    Papadopoulou, K.
    Kosmidis, P.
    Pectasides, D.
    Fountzilas, G.
    PHARMACOGENOMICS JOURNAL, 2014, 14 (03): : 248 - 255
  • [27] Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel
    A K Koutras
    V Kotoula
    C Papadimitriou
    D Dionysopoulos
    F Zagouri
    H P Kalofonos
    H P Kourea
    D V Skarlos
    E Samantas
    K Papadopoulou
    P Kosmidis
    D Pectasides
    G Fountzilas
    The Pharmacogenomics Journal, 2014, 14 : 248 - 255
  • [28] Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone
    Aldridge, SE
    Lennard, TWJ
    Williams, JR
    Birch, MA
    BRITISH JOURNAL OF CANCER, 2005, 92 (08) : 1531 - 1537
  • [29] Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone
    S E Aldridge
    T W J Lennard
    J R Williams
    M A Birch
    British Journal of Cancer, 2005, 92 : 1531 - 1537
  • [30] Vascular Endothelial Growth Factor (VEGF) Pathway Polymorphisms and Esophageal Cancer Outcome
    Eng, Lawson
    Azad, Abul Kalam
    Qiu, Xin
    Cheng, Dangxiao
    Tse, Alvina
    Faluyi, Olusola
    Renouf, Daniel J.
    Marsh, Sharon
    Savas, Sevtap
    Knox, Jennifer J.
    Darling, Gail E.
    Wong, Rebecca K. S.
    Xu, Wei
    Liu, Geoffrey
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 186 - 186
12345